The object of this study was to evaluate the metabolism of oxycodone to oxymorphone in a pain patient population using a quantitative liquid chromatography -tandem mass spectrometry analysis of 32,656 urine specimens obtained from pain patients between March 2008 and Feb 2010. The observed excretion was modeled using logarithmic transformation and approximated a Gaussian distribution. Oxycodone excretion into urine had a geometric mean of 1.93 mg/g of creatinine and oxymorphone had a value of 0.41 mg/g of creatinine. Increasing concentrations of oxycodone correlated with a smaller proportion of oxymorphone excretion suggesting saturation of oxycodone metabolism. Urine samples containing oxycodone without oxymorphone allowed an estimation of the proportion of poor metabolizers (2.4 + + + + + 2.1%) in the population. A similar analysis of samples containing oxymorphone without oxycodone gave an estimate of the proportion of ultra-rapid metabolizers (1.8 + + + + + 1.1%) in the population. Samples with concentrations of oxycodone above 10 mg/g of creatinine showed a sub-population of subjects with metabolic ratios roughly 100-fold less than the linear predictive model in this study. This study describes typical ranges for oxycodone and oxymorphone in urine, and showed that it is possible to identify fast or slow metabolizers who may be at risk for adverse events.
Introduction
Although oxycodone has a high potential for abuse (1) , its higher potency and fewer side effects than morphine (2) make it one of the most prevalent medications used clinically to treat pain patients for moderate to severe pain. Despite its popularity, oxycodone pharmacodynamics and concentrations of its metabolite, oxymorphone, are less well established (3) . Oxycodone is metabolized by CYP2D6 to oxymorphone, as presented in Figure 1 (4) . Oxymorphone itself is a pharmacodynamically active compound that is twice as potent as oxycodone and is also available in oral formulation (3, 5) . Oxymorphone also has a longer half-life than oxycodone and is commonly dosed every 6 hours, whereas the immediate release of oxycodone is more frequently dosed every 4 -6 hours (6) . Oxycodone binds to multiple opioid receptors, including m, l and d-opioid, whereas oxymorphone only binds to the m-opioid receptor (5, 7) . Although binding to l-opioid receptors has different pharmacodynamic effects than binding to m-opioid receptors, little information has been published regarding the relationship between the concentrations of oxycodone and oxymorphone in subjects taking oxycodone. Some reports downplay the role of the metabolite oxymorphone. One states that the concentrations of free oxymorphone in blood and in urine are negligible and so cannot be responsible for the m-opioid effects (7) . However, increased metabolism by CYP2D6 ultra-rapid metabolizers exhibits an increased pharmacodynamic effect from oxycodone use (4) . More detailed data regarding the metabolism of oxycodone to oxymorphone would help assess the amount of oxymorphone formed and its relationship to the administered oxycodone.
This retrospective study was conducted to describe the population variability in the metabolic ratio of oxymorphone to oxycodone in urine with the goal of establishing values that would allow physicians to determine whether or not their patients fall within the normal range. Assessing the expected relationship between the concentrations of oxycodone and oxymorphone may help explain differences in efficacy and toxicity. The frequency of specimens containing no oxymorphone or oxymorphone and no oxycodone were also analyzed. A separate objective of this study was to compare concentrations of oxymorphone in urine resulting from oxycodone metabolism to those from oxymorphone use.
Methods

Subject selection
Study specimens were collected from pain physician practices monitoring patients on chronic opioid therapy to meet guidelines suggested by the American Society of Interventional Pain Physicians and the American Society of Pain Medication (8 -10) . Specimens were shipped by overnight courier at ambient temperature. Many practices store specimens before pickup in refrigerators. On arrival, specimens were immediately processed for immunoassay and liquid chromatography -mass spectrometry (LC -MS) analysis. This study was conducted on de-identified subjects and was granted Institutional Review Board-exempt status by the University of California, San Diego Human Research Protection Program. The database used in this study contained 235,634 specimens with creatinine concentrations greater than 20 mg/dL. Specimens that had a creatinine concentration of less than 20 mg/dL were excluded because these were considered to be potentially tampered with (11) . Of these valid specimens, 68,834 had an oxycodone-containing medication listed. Of these, 49,176 had concentrations greater than the lower limit of quantitation of 50 ng/mL. These specimens were from 32,563 subjects. The urinary concentrations from these subjects with single or first visits were used in the calculations. Specimens included in this study were 32,563 urine specimens from subjects who have reported use of oxycodone but not oxymorphone, and had a creatinine concentration greater than 20 mg/dL. A flow chart of subject selection is presented in Figure 2 .
Analytical procedure An Agilent 1200 series binary pump SL liquid chromatography system, well plate sampler, thermostatted column compartment, paired with an Agilent 6410 QQQ mass spectrometer and Agilent Mass Hunter software was used for the analysis of all drugs. All specimens were tested by LC-MS-MS without prior immunoassay screening.
The method used an acetonitrile-aqueous formic acid gradient running at 0.4 mL/min. A 2.1 Â 50 mm, 1.8 mm Zorbax SB C 18 column was used for chromatography. The column temperature was 508C. Mobile phase A was 0.1% formic acid in water; B was 0.1% formic acid in acetonitrile. The Agilent 6410 Triple Quadrupole mass spectrometer was used in the positive electrospray ionization (ESI) mode. The nitrogen drying gas temperature was 3508C, and the flow was 12 L/min; nebulizer gas (nitrogen) was at 40 psi, and the capillary voltage was 3,000 V. Dwell times were 50 ms. HPLC water, acetonitrile, methanol and formic acid HPLC grade were obtained from VWR (Westchester, PA).
The following transition ions were used: oxycodone-D6, 322. Ion ratios for the qualifier ions were accepted if the variance was less than 20% from the target value. Deuterated internal standards of 100 mg/mL in methanol were obtained from Cerilliant Corporation (Round Rock, TX). Calibration solutions of 100, 200, 3,200 and 6,400 ng/mL were prepared by diluting the standards into synthetic urine (Microgenics, Fremont, CA). Deuterated internal standards were added to calibration solutions and to subject specimens to a final concentration of 1,200 ng/mL. Quality control specimens of 100 and 1,000 ng/mL were placed in each run. Upper limits of linearity were determined to be 100,000 ng/mL for all of the analytes by the dilution of the Cerilliant-certified standards into synthetic urine (Microgenics negative control). Quantitation of specimens with concentrations above 100,000 ng/mL were estimated through linear regression extrapolation from data below 100,000 ng/mL.
Ion suppression was corrected by use of the deuterated internal standards. The efficiency of the hydrolysis procedure was determined by use of morphine glucuronide controls set at 1,000 and 100 ng/mL. Morphine is used because, in this case, this assay tests for the presence of multiple drugs that are glucuronidated. Hydrolysis of the control material was considered acceptable if the value of the recovered morphine was above 90% of the nominal concentration.
Specimens were prepared for injection by incubating 25 mL of urine with 50 units of b-glucuronidase Type L-II from Patella vulgata (keyhole limpet) (Sigma-Aldrich, St. Louis, MO) in 50 mL 0.4M pH 4.5 acetate buffer for 3 h at 458C. Five microliters of the specimen were injected using a CT-PAL HTS injection device (CTC Analytics AG, Switzerland). Values greater than the upper limit of quantitation were extrapolated. The laboratory information system was that of Millennium Laboratories (San Diego, CA), which downloaded the instrument information into an Excel database.
The inter-assay coefficient of variation for all the analytes at the low and high ends of the quantitation curve were less than or equal to 10%. At 1,000 ng/mL, the coefficients of variation for oxycodone and oxymorphone were 6 and 7%, respectively, based on the analysis of more than 100 runs. Similarly, at 100 ng/mL, the coefficients of variation for oxycodone and oxymorphone were 7 and 10%, respectively. All quantitative data were obtained from calibration curves with R 2 . 0.95. Most were 0.99. The data were then re-exported as an Excel file from which the analyses were done. The allowed tolerance for the quantitative determination in these surveys is less than 20%.
Calculations
Statistical analyses were conducted using OriginPro 8.1 (OriginLab, Northampton, MA). The same data set was creatinine-normalized according to the formula:
(Drug level ng/mL 4 creatinine level mg/dL) Â 1/10 ¼ Drug level in mg/g creatinine.
These data were used to prepare the creatinine-normalized frequency distribution plots. To display data as a normal distribution, frequency plots were shown on a log scale. 
Intra-subject variability
The intra-subject variability in the metabolic ratio of oxymorphone to oxycodone from urine specimens was evaluated. Urine specimens from 1,546 subjects who provided four or more specimens during the study time frame were evaluated. The total number of specimens in this analysis was 8,752. The metabolic ratio in each specimen was determined, as was a geometric mean from each subject representing the intra-subject variability. All subjects had reported use of oxycodone but not oxymorphone, and had a creatinine concentration greater than 20 mg/dL (11) . Specimens with levels below quantitation of oxycodone and oxymorphone were not included in the study.
Comparison to oxymorphone concentrations resulting from oxymorphone use
The metabolite (oxymorphone) concentrations from oxycodone use were also compared to oxymorphone concentrations from subjects taking oral oxymorphone. The comparison group was obtained from 1,607 subjects reporting use of oxymorphone but not oxycodone, with measurable oxymorphone concentrations and creatinine concentrations greater than 20 mg/dL.
Glucuronidation evaluation
Due to the use of glucuronidase in this experiment, a separate analysis was conducted to assess the glucuronidation of oxycodone and oxymorphone. Specimens were quantitatively analyzed before and after hydrolysis with glucuronidase. Percent glucuronidation was calculated as the difference between the amounts before and after hydrolysis, divided by the amount before hydrolysis and multiplied by 100%.
Results
The ranges of urine concentration values were quite large. For this reason, logarithmic representations of the data were used. Figure 3A is a histogram showing the distribution of the urinary concentrations of creatinine-corrected oxycodone (mg/g cr). The data are plotted logarithmically and approximate a Gaussian distribution. The geometric mean was 1.93 mg/g cr and the 95% confidence interval (CI) of the mean was 1.92-1.94. The median was 2.24, with a 25th percentile of 0.70 and a 75th percentile of 6.33. These statistics are summarized in Table I . Figure 3B is a similar histogram showing distribution of the concentration of creatinine-corrected oxymorphone (mg/g cr).
The logarithmic plot also approximates a Gaussian distribution. The geometric mean for oxymorphone was 0.82 mg/g cr. The median was 0.85, with a 25th percentile of 0.26 and a 75th percentile of 2.74. These statistics are also summarized in Table I . These descriptive statistics show the expected range of urinary excretion values of subjects being prescribed oxycodone.
The metabolic ratios generated from the averages of intrasubject measurements are distributed roughly the same as the metabolic ratios of the population. This is demonstrated by their geometric means, which were very similar at 0.41 within subject and 0.48 in the population. From these values, it can be assumed that the individuals representing intra-subject variability in their metabolism are representative of individuals from the population. The interquartile ranges at 75th and 25th percentiles are 1.28 and 0.30, respectively, which is considerably smaller than within the population. Statistics for intra-subject variability are presented in Table II . The next analysis was performed to establish whether the metabolic pathway for conversion of oxycodone to oxymorphone was saturable. For this analysis, log creatinine-corrected oxycodone (mg/g cr) was plotted against log creatininecorrected oxymorphone (mg/g cr) ( Figure 4A Figure 4B is a plot of log creatinine-corrected oxycodone (mg/ g cr) versus log MR, (oxymorphone) / (oxycodone). A negative relationship is visible between creatinine-corrected oxycodone and the metabolic ratio [MR ¼ -0.45 Â log(amount oxycodone mg/g) -0.19, R2 ¼ 0.25, p , 0.0001], showing that as the concentration of oxycodone increases, there is a less than proportionate increase in oxymorphone formation.
As an attempt to better represent the variability in the metabolism of oxycodone, the variances in metabolism and metabolic ratio were calculated from a narrow range of excreted oxycodone. This allows us to examine the variability in metabolism that is possible at a single amount of oxycodone excreted, to prevent an overestimation in the variability that comes from looking at the entire population. A section of the range of values around the geometric mean concentration (1.93 mg/g) of Figure 4A was used. These values show a normal distribution in the amount of oxymorphone in each specimen. Statistics relevant to this distribution are displayed in Table III . As shown in Table III , the variability in the amount of oxymorphone at any given concentration of oxycodone is approximately 146.62 fold. A similar analysis was carried out using the MR for the same range of oxycodone. Again, a normal distribution of values was observed. The fold variance in this case was 146.01 fold. This analysis indicates that the variance in the amount of oxymorphone is smaller at any given amount of oxycodone than in the whole population, but is still quite variable.
The large population base allowed determination of the percent of ultra-rapid and poor metabolizers. For this analysis values of oxycodone and oxymorphone below 50 ng/mL were considered to contain no oxycodone or oxymorphone. A sigmoidal plot of the fraction of subjects with no oxymorphone versus increasing concentrations of oxycodone is presented in Figure 5A , which shows a decrease in the frequency of oxymorphone measurements below detection with increasing amounts of oxycodone. The terminal part of the analysis estimates the population of poor metabolizers. The sigmoidal fit estimates that 2.4 + 2.1% of the population are within the baseline that do not metabolize oxycodone into oxymorphone. Figure 5A , data points in red were not included in this fit. The red data points represent an increased frequency of specimens with no measured metabolite at high oxycodone concentrations and are likely a result of subjects attempting to falsely test positive (by adding oxycodone directly to urine).
In contrast, if subjects forming oxymorphone without measurable oxycodone are considered ultra-rapid metabolizers, a sigmoidal plot of the number of subjects with no oxycodone in their urine should allow extrapolation to calculate this number. As shown in Figure 5B , the likelihood of detecting oxymorphone but not oxycodone decreases with increasing concentration of oxymorphone. In this case, the sigmoidal fit predicts that 1.8 + 1.1% of the population exhibit ultra-rapid metabolism of oxycodone. There is the possibility that subjects may be using unreported oxymorphone, which would also result in values of oxymorphone with no oxycodone. This, however, is not visible in the data, because there is no sudden increase in the frequency of oxymorphone with no oxycodone around the frequency where oxymorphone use is distributed.
The distribution data of oxymorphone due to metabolism from oxycodone was used to approximate whether the urinary excretion values of oxymorphone formed by oxycodone excretion were comparable to those obtained from subjects prescribed oxymorphone alone. Figure 6 shows this comparison. The urinary concentrations had a large amount of overlap.
Both oxycodone and oxymorphone can be excreted as free drug and as a glucuronide. An analysis of 115 specimens from different subjects with varying amounts of oxycodone and oxymorphone are presented in Table IV . The data are expressed as the percent of the oxycodone and oxymorphone that was glucuronidated. For oxycodone, the estimated glucuronidation is 3%, while for oxymorphone the estimate is 93%. Examining oxymorphone excretion from subjects only prescribed oxymorphone showed that 99% of the oxymorphone was excreted as the glucuronidated form. Within experimental error, it appears that oxycodone is not excreted as the glucuronide, while oxymorphone is excreted as a glucuronide.
Discussion
The excretion histograms and the tabulated data in Table I should give practitioners interpreting urinary excretion data a range of expected values (12) . Interestingly, the log transformation of the data approximates a Gaussian distribution (13, 14) . Log/log graphical representation of the amount of oxycodone per gram of creatinine versus the amount of oxymorphone per gram of creatinine shows that increasing concentrations of oxycodone have a positive proportional relationship with oxymorphone. This supports previous work that oxymorphone is generated by the O-demethylation of oxycodone (15) . As the amount of oxycodone increases, a less than one-to-one increase in oxymorphone is observed, which indicates that decreasing proportional amounts of oxymorphone are excreted. Other possible explanations of the less-than-proportional, positive relationships include either saturation in the metabolism of oxycodone to oxymorphone or saturation of oxycodone reabsorption at higher concentrations. Plotting the amount of oxycodone per gram of creatinine versus the MR (oxymorphone/oxycodone) reveals a negative linear relationship. This again demonstrates that increasing amounts of oxycodone result in lesser proportions of oxymorphone due to saturation in metabolism or in the excretion of oxycodone. The origin of this effect may be either the glucuronidation or methylation steps of metabolism. Other possible explanations for these findings may be changes in protein binding, or renal clearance at higher concentrations.
A sub-population is highlighted in red in Figures 4A and B. These subjects exhibit a greatly decreased amount of oxymorphone at high concentrations of oxycodone (roughly 100-fold less). This may represent a buildup of oxycodone in these subjects due to decreased ability to metabolize oxycodone to oxymorphone due to genetic differences in oxycodone metabolism. It is possible that subjects might have attempted to falsely test positive by adding drug to their urine. However, a proportional relationship between oxycodone and oxymorphone in this sub-population suggests that this population has a different MR. In either case, subjects found in this population should be more closely monitored for toxicity and abuse.
As shown in Figure 4 , the amount of metabolite measured and the MR (oxymorphone/oxycodone) are dependent on the concentration of oxycodone. Variability in time after dose, dose amount, and genetics make it difficult to describe variability in the MR and in the metabolite formation in the population. Considering the standard deviation of the whole population and ignoring the concentration dependence would result in an overestimation in the variability. Examining the variability at a single concentration removes some degree of variability due to differences in dose and time after dose. Table III shows the variability at a single concentration of the geometric mean amount of oxycodone per gram of creatinine (+0.1). The normal distribution in this population represents variability at a single concentration, which better represents the variability that is possible at a single concentration. These results indicate that a given urine amount of oxycodone can result in an amount of oxymorphone and a metabolic ratio that varies approximately 146-fold.
The high degree of variability in the population compared to within an individual reflects variability in the pharmacogenomic distribution of CYP2D6 and CYP3A4 (16 -20) . The intrasubject variability is high, but is considerably less than the inter-subject variability and may be due to changes in dose amount and concomitant medications. The degree of variability in metabolism indicates that oxycodone use may lead to concentrations of oxymorphone similar to those visible with oxymorphone use.
Genetic distributions of the CYP2D6 gene indicate that a baseline sub-population of subjects within our population should have deficient CYP2D6 and therefore do not form oxymorphone from oxycodone (16) (17) (18) (19) (20) . This can be shown if a specimen has measurable oxycodone but not oxymorphone. However, due to variability in dose amount and time after dose, a specimen that has oxycodone but not oxymorphone is not always representative of a poor metabolizer. Specimens that have lower concentrations of drug may simply be towards the beginning or end of their dose interval and therefore have levels below detection by chance. The likelihood of detecting oxycodone but not oxymorphone decreases as a sigmoidal curve as the concentration of drug increases. This allows us to use this relationship in the entire population to estimate the subpopulation baseline, as shown in Figure 5 . Highlighted in red is an increase in the number of measurements with detectable oxycodone but no oxymorphone at high concentrations of oxycodone that were not included in the estimation. It is possible that these measurements are subjects attempting to falsely test positive for oxycodone by adding drug to their urine. This would result in high oxycodone with no metabolite.
In the same way that genetic distributions of the CYP2D6 gene lead to poor metabolizers, another sub-population metabolizes oxycodone more quickly than average. This results in specimens that contain measurable amounts of oxymorphone but not the parent drug, oxycodone. The likelihood of such measurements decreases with increasing concentration of oxycodone as a sigmoidal curve, allowing us to estimate the proportion of ultra-rapid metabolizers in our population. Subjects with increased metabolism have increased pharmacodynamics and possible toxicity (21) . The ability to determine whether a specimen falls in this category may help clinicians explain patient outcomes.
Comparing the use of oxymorphone to the concentrations of oxymorphone due to oxycodone use reveals that their Figure 6 . Comparison of oxymorphone use to oxymorphone due to metabolism of oxycodone. Data from oxymorphone due to metabolism were taken from 31,473 subjects reporting use of oxycodone that had positive levels of oxymorphone. Data from oxymorphone use were generated from 1,599 subjects reporting use of oxymorphone. For comparative purposes, the number of subject frequencies have been normalized by taking the largest peak to be 1.0 to account for the difference in population size.
distributions have considerable overlap in the amount of oxymorphone found in the urine. Considering the amount of overlap and the large variability in metabolism, it is likely that oxycodone use will, at some point in treatment, generate concentrations of oxymorphone similar to those observed with oxymorphone use. This suggests that concomitant use may lead to high and possibly unsafe concentrations of oxymorphone (14, 22) . The glucuronidation hydrolysis data indicates that oxycodone is predominantly excreted as free oxycodone and that oxymorphone is predominantly excreted as glucuronide. Because both the oxymorphone from oxycodone metabolism and when administered as the active metabolite gave similar glucuronidation percent values, the excretion pathway requires the glucuronidated form in each case.
Conclusions
Concentrations of oxymorphone and oxycodone found in the urine exhibit a large variability in the MR (oxymorphone/oxycodone). The amount of oxymorphone found in the urine and the MR were found to have less than proportional positive relationships with the amount of oxycodone in the urine, indicating possible saturation in the metabolism or reabsorption pathways of oxycodone. It is possible to identify subjects found within sub-populations who exhibit abnormal metabolite formation compared to the linear model presented in this study. Proportions within the population of both ultra-rapid and poor metabolizers of oxycodone to oxymorphone have been estimated in this study. When comparing oxymorphone use to oxymorphone due to metabolism, the amount of oxymorphone was found to be higher in the case of oxymorphone use, however, these distributions of concentrations have considerable overlap. This may indicate that the variable amount of oxymorphone formed reflects the wide variance in analgesia between patients.
Limitations
This was a retrospective analysis conducted on urine specimens submitted for "medication" monitoring from "physicians' offices". Dose and time after dose were unknown. Liver and renal status of subjects in the population is unknown. Reported medications are listed by physicians that may, if not accurate, misrepresent subjects. Although these factors will affect metabolism and excretion of oxycodone, the data set was used to represent the pain patient population as a whole and no inferences about individual subjects were made.
